Follow
Jochen Sven Utikal, MD
Jochen Sven Utikal, MD
Professor for Dermatooncology, German Cancer Research Center and University Medical Center Mannheim
Verified email at dkfz.de
Title
Cited by
Cited by
Year
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
EM Van Allen, D Miao, B Schilling, SA Shukla, C Blank, L Zimmer, ...
Science 350 (6257), 207-211, 2015
26932015
Improved survival with MEK inhibition in BRAF-mutated melanoma
KT Flaherty, C Robert, P Hersey, P Nathan, C Garbe, M Milhem, ...
New England Journal of Medicine 367 (2), 107-114, 2012
25732012
Induced pluripotent stem cells generated without viral integration
M Stadtfeld, M Nagaya, J Utikal, G Weir, K Hochedlinger
Science 322 (5903), 945-949, 2008
22962008
Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution
N Maherali, R Sridharan, W Xie, J Utikal, S Eminli, K Arnold, M Stadtfeld, ...
Cell stem cell 1 (1), 55-70, 2007
22452007
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
U Sahin, E Derhovanessian, M Miller, BP Kloke, P Simon, M Löwer, ...
Nature 547 (7662), 222-226, 2017
21812017
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma
GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, ...
New England Journal of Medicine 371 (20), 1877-1888, 2014
19692014
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F De Braud, J Larkin, ...
The Lancet 386 (9992), 444-451, 2015
15302015
Immortalization eliminates a roadblock during cellular reprogramming into iPS cells
J Utikal, JM Polo, M Stadtfeld, N Maherali, W Kulalert, RM Walsh, A Khalil, ...
Nature 460 (7259), 1145-1148, 2009
10602009
A high-efficiency system for the generation and study of human induced pluripotent stem cells
N Maherali, T Ahfeldt, A Rigamonti, J Utikal, C Cowan, K Hochedlinger
Cell stem cell 3 (3), 340-345, 2008
7332008
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
GV Long, KT Flaherty, D Stroyakovskiy, H Gogas, E Levchenko, ...
Annals of Oncology 28 (7), 1631-1639, 2017
7152017
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
L Hofmann, A Forschner, C Loquai, SM Goldinger, L Zimmer, S Ugurel, ...
European journal of cancer 60, 190-209, 2016
6722016
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
U Sahin, P Oehm, E Derhovanessian, RA Jabulowsky, M Vormehr, ...
Nature 585 (7823), 107-112, 2020
6312020
Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
C Groth, X Hu, R Weber, V Fleming, P Altevogt, J Utikal, V Umansky
British journal of cancer 120 (1), 16-25, 2019
6252019
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
D Liu, B Schilling, D Liu, A Sucker, E Livingstone, L Jerby-Arnon, ...
Nature medicine 25 (12), 1916-1927, 2019
6192019
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
L Zimmer, SM Goldinger, L Hofmann, C Loquai, S Ugurel, I Thomas, ...
European journal of cancer 60, 210-225, 2016
5762016
Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression
S Eminli, J Utikal, K Arnold, R Jaenisch, K Hochedlinger
Stem cells 26 (10), 2467-2474, 2008
5052008
Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors
R Weber, V Fleming, X Hu, V Nagibin, C Groth, P Altevogt, J Utikal, ...
Frontiers in immunology 9, 1310, 2018
4782018
Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task
TJ Brinker, A Hekler, AH Enk, J Klode, A Hauschild, C Berking, B Schilling, ...
European Journal of Cancer 113, 47-54, 2019
4392019
Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression
V Fleming, X Hu, R Weber, V Nagibin, C Groth, P Altevogt, J Utikal, ...
Frontiers in immunology 9, 398, 2018
4312018
Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells
J Utikal, N Maherali, W Kulalert, K Hochedlinger
Journal of cell science 122 (19), 3502-3510, 2009
4162009
The system can't perform the operation now. Try again later.
Articles 1–20